Ochsner partners with Cleveland Clinic for $1.3M Cardiothoracic Surgical Trial Study

5 Jun 2019
Dr. Gene Parrino
Dr. Gene Parrino

Ochsner has partnered with Cleveland Clinic’s Cardiothoracic Collaborative Clinical Center for participation in the Cardiothoracic Surgical Trials Network (CTSN). Dr. Gene Parrino, Section Head of Thoracic and Cardiovascular Surgery at Ochsner, is the Ochsner Principal Investigator for the study.

This five-year, $1.3 million research program is intended to identify strategies for bringing proven therapies into clinical practice that improve the treatment of patients with cardiovascular disease. The National Institutes of Health (NIH) sought grant applications from pairs of hospitals. The Ochsner and Cleveland Clinic pairing is one of only 4 partnerships that were awarded this funding.

“This research program gives Ochsner, which is already doing very well with cardiothoracic patient interventions and outcomes, the opportunity to partner with Cleveland Clinic,” said Dr. Parrino. “We are excited to be involved with Cleveland Clinic, the NIH, and the other CTSN sites in establishing a new gold standard of care,” he added.

The study will also enrich the skills and knowledge of young surgical investigators by offering an opportunity to be an NIH scholar. This role, which may be filled by a junior surgical resident or other person interested in academic research, will serve as an introduction to complex clinical trials and their conduct. By doing so, the NIH hopes to establish the next generation of surgeon-researchers.

The Cardiothoracic Surgical Trials Network (CTSN) has conducted several clinically important randomized trials in heart valve disease, coronary artery disease, and heart failure. It is now expanding into implementation research with Ochsner as an affiliate site with the Clinical and Implementation Research Skills Program (CIRSP).

CTSN aims to foster a culture of rigorous scientific comparisons and to promote the evaluation of newer surgical techniques, devices, and innovative pharmaceutical and bioengineered products directed at improving cardiovascular disease outcomes in adult populations.

More information is available at www.ctsurgerynet.org.

Latest